{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T15:32:45Z","timestamp":1773502365403,"version":"3.50.1"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2016,9,2]],"date-time":"2016-09-02T00:00:00Z","timestamp":1472774400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2016,9,2]],"date-time":"2016-09-02T00:00:00Z","timestamp":1472774400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2016,11]]},"DOI":"10.1038\/leu.2016.206","type":"journal-article","created":{"date-parts":[[2016,9,2]],"date-time":"2016-09-02T09:19:00Z","timestamp":1472807940000},"page":"2127-2130","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Are mild\/moderate acquired idiopathic aplastic anaemia and low-risk myelodysplastic syndrome one or two diseases or both and how should it\/they be treated?"],"prefix":"10.1038","volume":"30","author":[{"given":"S","family":"Nakao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R P","family":"Gale","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,9,2]]},"reference":[{"key":"BFleu2016206_CR1","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1182\/blood-2006-03-010777","volume":"108","author":"NS Young","year":"2006","unstructured":"Young NS, Calado RT, Scheinberg P . Current concepts in the pathophysiology and treatment of aplastic anemia. Blood 2006; 108: 2509\u20132519.","journal-title":"Blood"},{"key":"BFleu2016206_CR2","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1016\/j.leukres.2007.03.015","volume":"31","author":"F Wimazal","year":"2007","unstructured":"Wimazal F, Fonatsch C, Thalhammer R, Schwarzinger I, Mullauer L, Sperr WR et al. Idiopathic cytopenia of undetermined significance (ICUS) versus low risk MDS: the diagnostic interface. Leuk Res 2007; 31: 1461\u20131468.","journal-title":"Leuk Res"},{"key":"BFleu2016206_CR3","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1182\/blood.V60.5.1173.1173","volume":"60","author":"R Hoffman","year":"1982","unstructured":"Hoffman R, Bruno E, Elwell J, Mazur E, Gewirtz AM, Dekker P et al. Acquired amegakaryocytic thrombocytopenic purpura: a syndrome of diverse etiologies. Blood 1982; 60: 1173\u20131178.","journal-title":"Blood"},{"key":"BFleu2016206_CR4","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1111\/bjh.13853","volume":"172","author":"SB Killick","year":"2016","unstructured":"Killick SB, Bown N, Cavenagh J, Dokal I, Foukaneli T, Hill A et al. Guidelines for the diagnosis and management of adult aplastic anaemia. Br J Haematol 2016; 172: 187\u2013207.","journal-title":"Br J Haematol"},{"key":"BFleu2016206_CR5","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1111\/j.1365-2141.1995.tb05356.x","volume":"91","author":"N Tuzuner","year":"1995","unstructured":"Tuzuner N, Cox C, Rowe JM, Watrous D, Bennett JM . Hypocellular myelodysplastic syndromes (MDS): new proposals. Br J Haematol 1995; 91: 612\u2013617.","journal-title":"Br J Haematol"},{"key":"BFleu2016206_CR6","doi-asserted-by":"publisher","first-page":"264","DOI":"10.3324\/haematol.13755","volume":"94","author":"JM Bennett","year":"2009","unstructured":"Bennett JM, Orazi A . Diagnostic criteria to distinguish hypocellular acute myeloid leukemia from hypocellular myelodysplastic syndromes and aplastic anemia: recommendations for a standardized approach. Haematologica 2009; 94: 264\u2013268.","journal-title":"Haematologica"},{"key":"BFleu2016206_CR7","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1038\/leu.2014.161","volume":"29","author":"MG Della Porta","year":"2015","unstructured":"Della Porta MG, Travaglino E, Boveri E, Ponzoni M, Malcovati L, Papaemmanuil E et al. Minimal morphological criteria for defining bone marrow dysplasia: a basis for clinical implementation of WHO classification of myelodysplastic syndromes. Leukemia 2015; 29: 66\u201375.","journal-title":"Leukemia"},{"key":"BFleu2016206_CR8","doi-asserted-by":"publisher","first-page":"723","DOI":"10.3324\/haematol.2011.056879","volume":"97","author":"S Parmentier","year":"2012","unstructured":"Parmentier S, Schetelig J, Lorenz K, Kramer M, Ireland R, Schuler U et al. Assessment of dysplastic hematopoiesis: lessons from healthy bone marrow donors. Haematologica 2012; 97: 723\u2013730.","journal-title":"Haematologica"},{"key":"BFleu2016206_CR9","doi-asserted-by":"publisher","first-page":"2477","DOI":"10.1056\/NEJMoa1409405","volume":"371","author":"G Genovese","year":"2014","unstructured":"Genovese G, Kahler AK, Handsaker RE, Lindberg J, Rose SA, Bakhoum SF et al. Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. N Engl J Med 2014; 371: 2477\u20132487.","journal-title":"N Engl J Med"},{"key":"BFleu2016206_CR10","doi-asserted-by":"publisher","first-page":"2488","DOI":"10.1056\/NEJMoa1408617","volume":"371","author":"S Jaiswal","year":"2014","unstructured":"Jaiswal S, Fontanillas P, Flannick J, Manning A, Grauman PV, Mar BG et al. Age-related clonal hematopoiesis associated with adverse outcomes. N Engl J Med 2014; 371: 2488\u20132498.","journal-title":"N Engl J Med"},{"key":"BFleu2016206_CR11","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.1038\/nm.3733","volume":"20","author":"M Xie","year":"2014","unstructured":"Xie M, Lu C, Wang J, McLellan MD, Johnson KJ, Wendl MC et al. Age-related mutations associated with clonal hematopoietic expansion and malignancies. Nat Med 2014; 20: 1472\u20131478.","journal-title":"Nat Med"},{"key":"BFleu2016206_CR12","doi-asserted-by":"publisher","first-page":"1903","DOI":"10.1002\/pbc.25140","volume":"61","author":"R Nishimura","year":"2014","unstructured":"Nishimura R, Mase S, Araki R, Fujiki T, Kuroda R, Maeba H et al. Massive hyper-reactive hematopoietic nests in bilateral iliac bones in a patient with mild aplastic anemia. Pediatr Blood Cancer 2014; 61: 1903\u20131904.","journal-title":"Pediatr Blood Cancer"},{"issue":"5","key":"BFleu2016206_CR13","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1182\/blood-2009-03-209262","volume":"114","author":"J. W. Vardiman","year":"2009","unstructured":"Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 2009; 114: 937\u2013951.","journal-title":"Blood"},{"key":"BFleu2016206_CR14","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.3324\/haematol.2011.061127","volume":"97","author":"K Hosokawa","year":"2012","unstructured":"Hosokawa K, Katagiri T, Sugimori N, Ishiyama K, Sasaki Y, Seiki Y et al. Favorable outcome of patients who have 13q deletion: a suggestion for revision of the WHO 'MDS-U' designation. Haematologica 2012; 97: 1845\u20131849.","journal-title":"Haematologica"},{"key":"BFleu2016206_CR15","doi-asserted-by":"publisher","first-page":"e46","DOI":"10.3324\/haematol.2012.082875","volume":"98","author":"A Holbro","year":"2013","unstructured":"Holbro A, Jotterand M, Passweg JR, Buser A, Tichelli A, Rovo A . Comment to \"Favorable outcome of patients who have 13q deletion: a suggestion for revision of the WHO 'MDS-U' designation\" Haematologica. 2012;97(12):1845-9. Haematologica 2013; 98: e46\u2013e47.","journal-title":"Haematologica"},{"key":"BFleu2016206_CR16","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1007\/s12185-013-1324-x","volume":"97","author":"H Yamazaki","year":"2013","unstructured":"Yamazaki H, Nakao S . Border between aplastic anemia and myelodysplastic syndrome. Int J Hematol 2013; 97: 558\u2013563.","journal-title":"Int J Hematol"},{"key":"BFleu2016206_CR17","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1200\/JCO.2010.31.2686","volume":"29","author":"JR Passweg","year":"2011","unstructured":"Passweg JR, Giagounidis AA, Simcock M, Aul C, Dobbelstein C, Stadler M et al. Immunosuppressive therapy for patients with myelodysplastic syndrome: a prospective randomized multicenter phase III trial comparing antithymocyte globulin plus cyclosporine with best supportive care\u2014SAKK 33\/99. J Clin Oncol 2011; 29: 303\u2013309.","journal-title":"J Clin Oncol"},{"key":"BFleu2016206_CR18","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1056\/NEJMoa1414799","volume":"373","author":"T Yoshizato","year":"2015","unstructured":"Yoshizato T, Dumitriu B, Hosokawa K, Makishima H, Yoshida K, Townsley D et al. Somatic mutations and clonal hematopoiesis in aplastic anemia. N Engl J Med 2015; 373: 35\u201347.","journal-title":"N Engl J Med"},{"key":"BFleu2016206_CR19","doi-asserted-by":"publisher","first-page":"2698","DOI":"10.1182\/blood-2014-05-574889","volume":"124","author":"AG Kulasekararaj","year":"2014","unstructured":"Kulasekararaj AG, Jiang J, Smith AE, Mohamedali AM, Mian S, Gandhi S et al. Somatic mutations identify a subgroup of aplastic anemia patients who progress to myelodysplastic syndrome. Blood 2014; 124: 2698\u20132704.","journal-title":"Blood"},{"key":"BFleu2016206_CR20","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1182\/blood-2016-01-636381","volume":"128","author":"S Ogawa","year":"2016","unstructured":"Ogawa S . Clonal hematopoiesis in acquired aplastic anemia. Blood 2016; 128: 337\u2013347.","journal-title":"Blood"},{"key":"BFleu2016206_CR21","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1182\/blood.V78.1.163.163","volume":"78","author":"SD Nimer","year":"1991","unstructured":"Nimer SD, Golde DW, Kwan K, Lee K, Clark S, Champlin R . In vitro production of granulocyte-macrophage colony-stimulating factor in aplastic anemia: possible mechanisms of action of antithymocyte globulin. Blood 1991; 78: 163\u2013168.","journal-title":"Blood"},{"key":"BFleu2016206_CR22","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1182\/blood-2005-06-2485","volume":"107","author":"C Sugimori","year":"2006","unstructured":"Sugimori C, Chuhjo T, Feng X, Yamazaki H, Takami A, Teramura M et al. Minor population of CD55-CD59- blood cells predicts response to immunosuppressive therapy and prognosis in patients with aplastic anemia. Blood 2006; 107: 1308\u20131314.","journal-title":"Blood"},{"key":"BFleu2016206_CR23","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1111\/bjh.12661","volume":"164","author":"A Kulagin","year":"2014","unstructured":"Kulagin A, Lisukov I, Ivanova M, Golubovskaya I, Kruchkova I, Bondarenko S et al. Prognostic value of paroxysmal nocturnal haemoglobinuria clone presence in aplastic anaemia patients treated with combined immunosuppression: results of two-centre prospective study. Br J Haematol 2014; 164: 546\u2013554.","journal-title":"Br J Haematol"},{"key":"BFleu2016206_CR24","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1111\/bjh.12656","volume":"164","author":"PR Tutelman","year":"2014","unstructured":"Tutelman PR, Aubert G, Milner RA, Dalal BI, Schultz KR, Deyell RJ . Paroxysmal nocturnal haemoglobinuria phenotype cells and leucocyte subset telomere length in childhood acquired aplastic anaemia. Br J Haematol 2014; 164: 717\u2013721.","journal-title":"Br J Haematol"},{"key":"BFleu2016206_CR25","doi-asserted-by":"publisher","first-page":"6601","DOI":"10.1182\/blood-2011-07-365189","volume":"118","author":"T Katagiri","year":"2011","unstructured":"Katagiri T, Sato-Otsubo A, Kashiwase K, Morishima S, Sato Y, Mori Y et al. Frequent loss of HLA alleles associated with copy number-neutral 6pLOH in acquired aplastic anemia. Blood 2011; 118: 6601\u20136609.","journal-title":"Blood"},{"issue":"10","key":"BFleu2016206_CR26","doi-asserted-by":"publisher","first-page":"931-939.e3","DOI":"10.1016\/j.exphem.2016.05.013","volume":"44","author":"Hiroyuki Maruyama","year":"2016","unstructured":"Maruyama H, Katagiri T, Kashiwase K, Shiina T, Sato-Otsubo A, Zaimoku Y et al. Clinical significance and origin of leukocytes that lack HLA-A allele expression in patients with acquired aplastic anemia. Exp Hematol 2016; e-pub ahead of print 29 May 2016 doi:10.1016\/j.exphem.2016.05.013.","journal-title":"Experimental Hematology"},{"key":"BFleu2016206_CR27","doi-asserted-by":"publisher","first-page":"2160","DOI":"10.1182\/blood-2008-02-141325","volume":"112","author":"K Mochizuki","year":"2008","unstructured":"Mochizuki K, Sugimori C, Qi Z, Lu X, Takami A, Ishiyama K et al. Expansion of donor-derived hematopoietic stem cells with PIGA mutation associated with late graft failure after allogeneic stem cell transplantation. Blood 2008; 112: 2160\u20132162.","journal-title":"Blood"},{"key":"BFleu2016206_CR28","doi-asserted-by":"publisher","first-page":"901","DOI":"10.3324\/haematol.2012.066217","volume":"98","author":"Y Seiki","year":"2013","unstructured":"Seiki Y, Sasaki Y, Hosokawa K, Saito C, Sugimori N, Yamazaki H et al. Increased plasma thrombopoietin levels in patients with myelodysplastic syndrome: a reliable marker for a benign subset of bone marrow failure. Haematologica 2013; 98: 901\u2013907.","journal-title":"Haematologica"},{"key":"BFleu2016206_CR29","doi-asserted-by":"publisher","first-page":"5166","DOI":"10.1200\/JCO.2010.29.7010","volume":"28","author":"EM Sloand","year":"2010","unstructured":"Sloand EM, Olnes MJ, Shenoy A, Weinstein B, Boss C, Loeliger K et al. Alemtuzumab treatment of intermediate-1 myelodysplasia patients is associated with sustained improvement in blood counts and cytogenetic remissions. J Clin Oncol 2010; 28: 5166\u20135173.","journal-title":"J Clin Oncol"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/leu2016206.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/leu2016206","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/leu2016206.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,10]],"date-time":"2022-06-10T10:05:17Z","timestamp":1654855517000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/leu2016206"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9,2]]},"references-count":29,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2016,11]]}},"alternative-id":["BFleu2016206"],"URL":"https:\/\/doi.org\/10.1038\/leu.2016.206","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,9,2]]},"assertion":[{"value":"2 September 2016","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"RPG is a part-time employee of Celgene Corp.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}